Grant Life Sciences gets IP boost for cervical cancer blood test
This article was originally published in Clinica
Moving forward with development plans for its cervical cancer blood test, US firm Grant Life Sciences (GLS) has secured key intellectual property covering the product's fundamental technology. The test, which is currently undergoing validation studies, promises to offer a more reliable alternative to the Pap smear.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.